Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and Biosecurity
Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and Biosecurity (August 29, 2023) | By Ginkgo Bioworks. Ginkgo and Google Cloud enter strategic
Ginkgo Bioworks Awarded DARPA Contract to Reimagine the Manufacturing of Complex Therapeutic Proteins
Ginkgo Bioworks Awarded DARPA Contract to Reimagine the Manufacturing of Complex Therapeutic Proteins (July 19, 2023) | By BioSpace. ARLINGTON, Va. and BOSTON, July 19, 2023 /PRNewswire/ — Approved for
DTx Pharma announces acquisition by Novartis
DTx Pharma announces acquisition by Novartis (July 17, 2023) | By Christina Trout – DTx Pharma. DTx Pharma’s Fatty Acid Ligand Conjugated Oligonucleotide (FALCON™) platform facilitates extra-hepatic delivery of siRNA therapeutics
Takeda, F-star Sign Potential $1B Immuno-Oncology Agreement
Takeda, F-star Sign Potential $1B Immuno-Oncology Agreement (July 7, 2023) | By Tristan Manalac. Takeda has entered into a strategic discovery collaboration and licensing agreement with British biotech F-star
Lilly Aims to Boost Immuno Business with $2.4B DICE Buy
Lilly Aims to Boost Immuno Business with $2.4B DICE Buy (June 20, 2023) | By Tristan Manalac. To deepen its autoimmune disease portfolio, Eli Lilly is acquiring California-based biopharma DICE
Boehringer and Ginkgo Ink Potential $400M+ Metagenomics Deal for “Undruggable” Targets
Boehringer and Ginkgo Ink Potential $400M+ Metagenomics Deal for “Undruggable” Targets (May 8, 2023) | By Inside Precision Medicine. Ginkgo Bioworks today announced a new partnership with Boehringer Ingelheim to
Biomica Announces Closing of $20 Million Financing Round led by Shanghai Healthcare Capital
Biomica Announces Closing of $20 Million Financing Round led by Shanghai Healthcare Capital (April 27, 2023) | By Biomica Ltd. REHOVOT, Israel, April 27, 2023 /PRNewswire/ — Biomica Ltd., a
Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies Financing will enable pivotal Phase 3 study of VE303 for recurrent C. difficile infection, to begin
DSM agrees terms to acquire postbiotics pioneer Adare Biome
DSM agrees terms to acquire postbiotics pioneer Adare Biome (April 19, 2023) | By Microbiome Times. Royal DSM, a global science-based leader in health, nutrition, and bioscience, announces that it
Ginkgo, hunting for biotech platforms that ‘collect dust,’ scoops up AAV gene therapy capsid specialist
Ginkgo, hunting for biotech platforms that ‘collect dust,’ scoops up AAV gene therapy capsid specialist (April 5, 2023) | By Annalee Armstrong. Ginkgo Bioworks doesn’t want the biotech industry’s therapies.